Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.It is often difficult to treat, requires a ...

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...